Expression of Idh1R132H in the Murine Subventricular Zone Stem Cell Niche Recapitulates Features of Early Gliomagenesis
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Isocitrate dehydrogenase 1 mutations drive human gliomagenesis, probably through neomorphic enzyme activity that produces D-2-hydroxyglutarate. To model this disease, we conditionally expressed Idh1 R132H in the subventricular zone (SVZ) of the adult mouse brain. The mice developed hydrocephalus and grossly dilated lateral ventricles, with accumulation of 2-hydroxyglutarate and reduced α-ketoglutarate. Stem and transit amplifying/progenitor cell populations were expanded, and proliferation increased. Cells expressing SVZ markers infiltrated surrounding brain regions. SVZ cells also gave rise to proliferative subventricular nodules. DNA methylation was globally increased, while hydroxymethylation was decreased. Mutant SVZ cells overexpressed Wnt, cell-cycle and stem cell genes, and shared an expression signature with human gliomas. Idh1 R132H mutation in the major adult neurogenic stem cell niche causes a phenotype resembling gliomagenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575 · cited 1×
“This analysis also showed significant increases in gene sets specific to human glioblastomas, including the proneural sub-type, which is characterized by mutation of IDH1 (Verhaak et al., 2010) (Figures 8F and S6E).”
BackgroundAn Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 2×
“In gliomas, IDH1 is the most common mutation (Parsons et al., 2008).”
BackgroundIDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus
Srinivas, S., Watanabe, T., Lin, C.-S., William, C. M., Tanabe, Y., Jessell, T. M., & Costantini, F. (2001) · BMC Developmental Biology · doi:10.1186/1471-213x-1-4 · Cited by 3,121
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766 · cited 10×
“…(5hmC) (Xu et al., 2011), and prolyl hydroxylases (PHDs) that have targets such as HIF1a and collagen (Borger et al., 2012; Chowdhury et al., 2011; Duncan et al., 2012; Figueroa et al., 2010; Hirata et al., 2015; Lu et al., 2012; Sasaki et al., 2012b; Tarhonskaya et al., 2014; Xu et al., 2011).”
BackgroundInfluentialRecurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219 · cited 4×
“Cancer Cell 30, 578–594, October 10, 2016 591 mutually exclusive in AML (Figueroa et al., 2010; Gaidzik et al., 2012), and it has been reported that expression of mutant IDH or administration of 2HG can inhibit TET2 in vitro and in vivo, resulting in decreased production of 5hmC (Figueroa et al., 2010; Sasaki et al.,…”
BackgroundInfluentialIDH mutation impairs histone demethylation and results in a block to cell differentiation
Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., et al. (2012) · Nature · doi:10.1038/nature10860 · Cited by 1,985
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. K. H., Li, X. S., Woon, E. C. Y., Yang, M., et al. (2011) · The EMBO Reports · doi:10.1038/embor.2011.43 · Cited by 1,035 · cited 2×
“…50-hydroxymethylcytosine (5hmC) (Xu et al., 2011), and prolyl hydroxylases (PHDs) that have targets such as HIF1a and collagen (Borger et al., 2012; Chowdhury et al., 2011; Duncan et al., 2012; Figueroa et al., 2010; Hirata et al., 2015; Lu et al., 2012; Sasaki et al., 2012b; Tarhonskaya et al.,…”
BackgroundSelf-citationTETonic shift: biological roles of TET proteins in DNA demethylation and transcription
Pastor, W. A., Aravind, L., & Rao, A. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3589 · Cited by 897 · cited 2×
“…Gaidzik et al., 2012), and it has been reported that expression of mutant IDH or administration of 2HG can inhibit TET2 in vitro and in vivo, resulting in decreased production of 5hmC (Figueroa et al., 2010; Sasaki et al., 2012a; Xu et al., 2011) and reduced DNA demethylation (Pastor et al., 2013).”
BackgroundBorger, D. R., Tanabe, K. K., Fan, K. C., Lopez, H. U., Fantin, V. R., Straley, K. S., Schenkein, D. P., Hezel, A. F., Ancukiewicz, M., Liebman, H. M., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0386 · Cited by 728
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
Losman, J.-A., & Kaelin, W. G. (2013) · Genes & Development · doi:10.1101/gad.217406.113 · Cited by 570
Reitman, Z. J., & Yan, H. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq187 · Cited by 562 · cited 2×
“IDH2 localizes to themitochondria, where it regulates the tricarboxylic acid (TCA) cycle (Reitman and Yan, 2010).”
BackgroundPansuriya, T. C., van Eijk, R., d'Adamo, P., van Ruler, M. A. J. H., Kuijjer, M. L., Oosting, J., Cleton-Jansen, A.-M., van Oosterwijk, J. G., Verbeke, S. L. J., Meijer, D., et al. (2011) · Nature Genetics · doi:10.1038/ng.1004 · Cited by 559 · cited 2×
“, 2012), enchondroma (Amary et al., 2011; Pansuriya et al., 2011), chondrosarcoma (Amary et al.”
BackgroundIDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics
Sasaki, M., Knobbe, C. B., Munger, J. C., Lind, E. F., Brenner, D., Brüstle, A., Harris, I. S., Holmes, R., Wakeham, A., Haight, J., et al. (2012) · Nature · doi:10.1038/nature11323 · Cited by 513 · cited 5×
“…(5hmC) (Xu et al., 2011), and prolyl hydroxylases (PHDs) that have targets such as HIF1a and collagen (Borger et al., 2012; Chowdhury et al., 2011; Duncan et al., 2012; Figueroa et al., 2010; Hirata et al., 2015; Lu et al., 2012; Sasaki et al., 2012b; Tarhonskaya et al., 2014; Xu et al., 2011).”
BackgroundMethodInfluentialSasaki, M., Knobbe, C. B., Itsumi, M., Elia, A. J., Harris, I. S., Chio, I. I. C., Cairns, R. A., McCracken, S., Wakeham, A., Haight, J., et al. (2012) · Genes & Development · doi:10.1101/gad.198200.112 · Cited by 296 · cited 5×
“…(5hmC) (Xu et al., 2011), and prolyl hydroxylases (PHDs) that have targets such as HIF1a and collagen (Borger et al., 2012; Chowdhury et al., 2011; Duncan et al., 2012; Figueroa et al., 2010; Hirata et al., 2015; Lu et al., 2012; Sasaki et al., 2012b; Tarhonskaya et al., 2014; Xu et al., 2011).”
BackgroundMethodInfluentialGaidzik, V. I., Paschka, P., Späth, D., Habdank, M., Köhne, C.-H., Germing, U., von Lilienfeld-Toal, M., Held, G., Horst, H.-A., Haase, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.2886 · Cited by 185
Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review
Aghili, M., Zahedi, F., & Rafiee, E. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9706-2 · Cited by 159 · cited 1×
“D2HGwas postulated to be an ‘‘oncometabolite’’ based on reports of brain tumors in patients with congenital L2HGDH (L-2-hydroxyglutarate dehydrogenase) deficiency, in whom L2HG accumulates because it cannot be metabolized to aKG (Aghili et al., 2009; Moroni et al., 2004; Patay et al., 2012, 2015).”
BackgroundMutant IDH is sufficient to initiate enchondromatosis in mice
Hirata, M., Sasaki, M., Cairns, R. A., Inoue, S., Puviindran, V., Li, W. Y., Snow, B. E., Jones, L. D., Wei, Q., Sato, S., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424400112 · Cited by 115 · cited 2×
“, 2011), and prolyl hydroxylases (PHDs) that have targets such as HIF1a and collagen (Borger et al., 2012; Chowdhury et al., 2011; Duncan et al., 2012; Figueroa et al., 2010; Hirata et al., 2015; Lu et al., 2012; Sasaki et al., 2012b; Tarhonskaya et al., 2014; Xu et al., 2011).”
BackgroundNon-enzymatic chemistry enables 2-hydroxyglutarate-mediated activation of 2-oxoglutarate oxygenases
Tarhonskaya, H., Rydzik, A. M., Leung, I. K. H., Loik, N. D., Chan, M. C., Kawamura, A., McCullagh, J. S. O., Claridge, T. D. W., Flashman, E., & Schofield, C. J. (2014) · Nature Communications · doi:10.1038/ncomms4423 · Cited by 80 · cited 2×
“, 2011), and prolyl hydroxylases (PHDs) that have targets such as HIF1a and collagen (Borger et al., 2012; Chowdhury et al., 2011; Duncan et al., 2012; Figueroa et al., 2010; Hirata et al., 2015; Lu et al., 2012; Sasaki et al., 2012b; Tarhonskaya et al., 2014; Xu et al., 2011).”
BackgroundSelf-citation
Cited by
Weller, M., Wen, P. Y., Chang, S. M., Dirven, L., Lim, M., Monje, M., & Reifenberger, G. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00516-y · Cited by 592
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate
Bunse, L., Pusch, S., Bunse, T., Sahm, F., Sanghvi, K., Friedrich, M., Alansary, D., Sonner, J. K., Green, E., Deumelandt, K., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0095-6 · Cited by 539
Glioblastoma stem cells: lessons from the tumor hierarchy in a lethal cancer
Gimple, R. C., Bhargava, S., Dixit, D., & Rich, J. N. (2019) · Genes & Development · doi:10.1101/gad.324301.119 · Cited by 514
Diffuse Glioma Heterogeneity and Its Therapeutic Implications
Nicholson, J. G., & Fine, H. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1474 · Cited by 460
Biological Role and Therapeutic Potential of IDH Mutations in Cancer
Waitkus, M. S., Diplas, B. H., & Yan, H. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.011 · Cited by 335
Metadata
- Authors
- Bardella, C., Al-Dalahmah, O., Krell, D., Brazauskas, P., Al-Qahtani, K., Tomkova, M., Adam, J., Serres, S., Lockstone, H., Freeman-Mills, L., Pfeffer, I., Sibson, N., Goldin, R., Schuster-Böeckler, B., Pollard, P. J., Soga, T., McCullagh, J. S., Schofield, C. J., Mulholland, P., Ansorge, O., Kriaucionis, S., Ratcliffe, P. J., Szele, F. G., & Tomlinson, I.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 30
- Issue
- 4
- Pages
- 578-594
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2526865897
- Cited by
- 150
- References
- 22
- FWCI
- 9.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.